- Trial phase
- Approved
- Time to market
- Already on the market. First FDA approval was June 27, 2018 for melanoma; NSCLC label expansion approved October 11, 2023.
- Why 4/10
- Mektovi is already FDA-approved and commercially marketed with no pending PDUFA date or pivotal readout in the next 12 months. As an approved product at a large diversified pharma, it lacks a hard binary catalyst, capping the impactScore at 4 per the rubric.
Mektovi has no pending PDUFA date or pivotal readout; the next meaningful event would be any future label expansion data (e.g., the ongoing Phase 2 pediatric craniopharyngioma trial), but that is years from a decision. For Pfizer investors, Mektovi is a steady-growth contributor within a diversified oncology portfolio; the more immediate binary catalysts for PFE stock are elsewhere (e.g., Elrexfio, pipeline readouts).
Price Chart
Executive Summary
Mektovi (binimetinib) is an FDA-approved oral MEK inhibitor developed by Pfizer (NYSE: PFE) through its acquisition of Array BioPharma. It is used exclusively in combination with Braftovi (encorafenib) to treat BRAF V600-mutant melanoma (approved 2018) and BRAF V600E-mutant metastatic non-small cell lung cancer (approved 2023). The combined Braftovi/Mektovi franchise generated $716 million in 2025 revenue (up 18% YoY) and continues to grow, with recent label approvals in the UK and Singapore. However, Mektovi has no pending PDUFA date or pivotal readout, and generic competition is emerging (Alembic received tentative FDA approval with 180-day exclusivity). For Pfizer, a $62+ billion diversified pharma, Mektovi is a steady but non-binary contributor within a broader oncology portfolio.
How It Works
Mektovi (binimetinib) is a targeted cancer pill that blocks MEK1 and MEK2, two proteins in the MAPK signaling pathway that cancer cells use to grow and divide. It is always given together with a BRAF inhibitor called Braftovi (encorafenib), which blocks a different part of the same pathway. This two-pronged attack is designed to more effectively shut down cancer growth in tumors that have a BRAF V600 mutation.
Trial Status
Mektovi is FDA-approved and commercially marketed in the U.S. for two indications: (1) BRAF V600E/K mutant unresectable or metastatic melanoma (COLUMBUS Phase 3 trial), and (2) BRAF V600E mutant metastatic NSCLC (PHAROS Phase 2 trial). It is also approved in the EU, UK, Singapore, and other markets. Ongoing trials include a Phase 2 study in pediatric adamantinomatous craniopharyngioma (NCT05286788) and various investigator-sponsored combination studies, but no new pivotal readouts are imminent.
The Two-Sided Case
Upcoming Catalysts
- No near-term PDUFA dates or pivotal readouts specifically for Mektovi. The next potential catalyst would be data from the ongoing Phase 2 pediatric craniopharyngioma trial or any future label-expansion filing, but neither is dated.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report